No profile data available.
Syros Pharmaceuticals, Inc. (SYRS) is a healthcare company in the blood disorder treatment drugs industry, based in Cambridge, United States, with about 68 full-time employees.
It reported revenue of $9.94 million for fiscal year 2023, down 33.2% from fiscal year 2022, and net income of -$164.57 million. In Q3 2024 (the quarter ended September 30, 2024) revenue was $0, down 100.0% from a year before. Its market capitalization was $10,732 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.
Syros Pharmaceuticals reported $9.94 million in revenue for fiscal year 2023, down 33.2% from $14.88 million in fiscal year 2022. In Q3 2024 revenue was $0.
$10,732 as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Coherus Oncology, Inc. (CHRS), Rallybio Corporation (RLYB), Emmaus Life Sciences, Inc. (EMMA).